Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

A $56 million boost for smart-lab developer Strateos

by Rick Mullin
June 11, 2021 | A version of this story appeared in Volume 99, Issue 22

 

A photo of one of Strateos's remote research labs.
Credit: Strateos
Strateos conducts remote drug research for companies at its labs in California.

Strateos, a developer of data management and robotic systems for drug discovery, has raised $56.1 million in a series B investment round led by DCVC and Lux Capital. The company operates small-molecule and biologic-drug labs in San Diego and Menlo Park, California, where customers can remotely conduct experiments. Strateos opened the San Diego lab last year in partnership with Eli Lilly and Company, an investor in the financing round. The company was founded in 2012 as Transcriptic.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.